ABOUT US
TASK provides world class clinical trial services with cost-efficient, timeous and accurate outcomes for Sponsors. This is achieved through the dedicated Phase I unit in Utrecht in collaboration with UMC Utrecht, as well as 6 clinical sites in South Africa offering Phase I – IV trial services from protocol development through to statistical analysis.
History
TASK’s first trial was conducted in 2005. To date the company has completed more than 100 projects for both international sponsors as well as consortiums, consisting of top academic and government institutions. TASK is a partner in the biggest Tuberculosis (TB) consortium in history with the ambitious goal of creating a new TB regiment.
2005
First trial in Cape Town, TMC207 (Bedaquiline)
2012
Registration of Bedaquiline, first new TB drug in 40 years.
2016
Professor Andreas Diacon awarded the 2016 Scientific Prize of the International Union Against Tuberculosis and Lung DIsease.
2018
Founder and CEO Andreas Diacon recognised by the Bill and Melinda Gates Foundation as a “Hero in the field”.
2022
First patient dosed in Phase 2a clinical trial with BVL-GSK098, representing a new concept of overcoming resistance and potentiating the activity of an existing antibiotic, for the treatment of tuberculosis (TB).
2022
Signed collaboration agreement with UMC Utrecht for Phase 1 clinical studies.
THERE IS MORE TO
Who We Are
VISION
Better healthcare for everyone.
MISSION
To provide a platform for the development of novelties in healthcare that benefit the community.
VALUES
- Innovation
- Accountability
- Agility
- Adaptability
